PMS-METOPROLOL-L TABLET

ประเทศ: แคนาดา

ภาษา: อังกฤษ

แหล่งที่มา: Health Canada

สารออกฤทธิ์:

METOPROLOL TARTRATE

มีจำหน่ายจาก:

PHARMASCIENCE INC

รหัส ATC:

C07AB02

INN (ชื่อสากล):

METOPROLOL

ปริมาณ:

100MG

แบบฟอร์มเภสัชกรรม:

TABLET

องค์ประกอบ:

METOPROLOL TARTRATE 100MG

เส้นทางการบริหาร:

ORAL

หน่วยในแพ็คเกจ:

100/500/1000

ประเภทใบสั่งยา:

Prescription

พื้นที่บำบัด:

BETA-ADRENERGIC BLOCKING AGENTS

สรุปสินค้า:

Active ingredient group (AIG) number: 0111923003; AHFS:

สถานะการอนุญาต:

APPROVED

วันที่อนุญาต:

1997-03-10

สรุปลักษณะสินค้า

PRODUCT MONOGRAPH
PR
PMS-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 24, 2020
www.pharmascience.com
SUBMISSION CONTROL NO: 240530
_pms-METOPROLOL-L Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
...............................